Isobio software: biological dose distribution
and biological dose volume histogram
from physical dose conversion using
linear-quadratic-linear model

Jaikuna, Tanwiwat; Khadsiri, Phatchareewan; Chawapun, Nisa; Saekho, Suwit; Tharavichitkul, Ekkasit

doi:10.5114/jcb.2017.66082

Cited by 2 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Jaikuna et al reported that it is useful to use the LQL model for the dose evaluation of radiotherapy in which the dose per fraction is high, such as in HDR brachytherapy and stereotactic radiation therapy, that the LQ model cannot be used. [24] Their report supports the propriety of our dose evaluation method.…”

Section: Discussionsupporting

confidence: 67%

Establishment of a new three-dimensional dose evaluation method considering variable relative biological effectiveness and dose fractionation in proton therapy combined with high-dose-rate brachytherapy

et al. 2019

View full text Add to dashboard Cite

Purpose:The purpose of this study is to evaluate the influence of variable relative biological effectiveness (RBE) of proton beam and dose fractionation has on dose distribution and to establish a new three-dimensional dose evaluation method for proton therapy combined with high-dose-rate (HDR) brachytherapy.Materials and Methods:To evaluate the influence of variable RBE and dose fractionation on dose distribution in proton beam therapy, the depth-dose distribution of proton therapy was compared with clinical dose, RBE-weighted dose, and equivalent dose in 2 Gy fractions using a linear-quadratic-linear model (EQD2LQL). The clinical dose was calculated by multiplying the physical dose by RBE of 1.1. The RBE-weighted dose is a biological dose that takes into account RBE variation calculated by microdosimetric kinetic model implemented in Monte Carlo code. The EQD2LQL is a biological dose that makes the RBE-weighted dose equivalent to 2 Gy using a linear-quadratic-linear (LQL) model. Finally, we evaluated the three-dimensional dose by taking into account RBE variation and LQL model for proton therapy combined with HDR brachytherapy.Results:The RBE-weighted dose increased at the distal of the spread-out Bragg peak (SOBP). With the difference in the dose fractionation taken into account, the EQD2LQL at the distal of the SOBP increased more than the RBE-weighted dose. In proton therapy combined with HDR brachytherapy, a divergence of 103% or more was observed between the conventional dose estimation method and the dose estimation method we propose.Conclusions:Our dose evaluation method can evaluate the EQD2LQL considering RBE changes in the dose distribution.

show abstract

Section: Discussionsupporting

confidence: 67%

Establishment of a new three-dimensional dose evaluation method considering variable relative biological effectiveness and dose fractionation in proton therapy combined with high-dose-rate brachytherapy

et al. 2019

View full text Add to dashboard Cite

show abstract

“…17 Another field for further development of dose constraints (even for normofractionated radio-therapy) would be taking into account the number of fractions and calculating dose constraints with equivalent dose 2 Gy (EQD2) correction. This strategy would allow for better comparison of dose constraints and side effects between different radiotherapy fractionation schedules as reported by Jaikuna et al 28…”

Section: Discussionmentioning

confidence: 99%

“…This strategy would allow for better comparison of dose constraints and side effects between different radiotherapy fractionation schedules as reported by Jaikuna et al . 28 …”

Section: Discussionmentioning

confidence: 99%

Hypofractionated preoperative radiotherapy for high risk soft tissue sarcomas in a geriatric patient population

Potkrajcic

Traub

Hermes

et al. 2021

Radiology and Oncology

View full text Add to dashboard Cite

Background Standard therapy for localised, resectable high risk soft tissue sarcomas consists of wide excision and radiotherapy over several weeks. This treatment schedule is hardly feasible in geriatric and frail patients. In order not to withhold radiotherapy from these patients, hypofractionated radiotherapy with 25 Gy in 5 fractions was evaluated in a geriatric patient population. Patients and methods A retrospective analysis was performed of 18 geriatric patients with resectable high risk soft tissue sarcomas of extremities and thoracic wall. Wound healing and short term oncologic outcome were analysed. In addition, dose constraints for radiotherapy of the extremities were transferred from normofractionated to hypofractionated radiotherapy regimens. Results Feasibility was good with 17/18 patients completing treatment as planned. Wound healing complication rate was in the range of published data. Two patients developed local and distant recurrence, two patients isolated distant recurrences. No isolated local recurrences were observed. Keeping the constraints was possible in all cases without compromising the coverage of the target volume. Conclusions Hypofractionated radiotherapy and surgery was well tolerated even in this specific patient population. With feasibility concerning early wound healing problems and adapted constraints, which allow for the treatment of most resectable extremity tumours, the concept warrants further evaluation in patients unfit for standard radiotherapy.

show abstract

Isobio software: biological dose distribution and biological dose volume histogram from physical dose conversion using linear-quadratic-linear model

Cited by 2 publications

References 10 publications

Establishment of a new three-dimensional dose evaluation method considering variable relative biological effectiveness and dose fractionation in proton therapy combined with high-dose-rate brachytherapy

Establishment of a new three-dimensional dose evaluation method considering variable relative biological effectiveness and dose fractionation in proton therapy combined with high-dose-rate brachytherapy

Hypofractionated preoperative radiotherapy for high risk soft tissue sarcomas in a geriatric patient population

Contact Info

Product

Resources

About